Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-Specific T-Cell Lines for EBV-Associated Lymphoma
NCT06391814Completed
- Start
- Jan 2024
- Primary completion
- Apr 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of EBV-specific cytotoxic T lymphocytes (Baylor College of Medicine) in Epstein-Barr virus associated lymphoma and hemophagocytic lymphohistiocytosis (HLH). Primary endpoint: Safety assessed by lack of graft-versus-host disease (GVHD) at 1 year. Started Jan 2024; status: completed.
02
Drugs
EBV-specific cytotoxic T lymphocytes (Baylor College of Medicine)
03
Conditions
Epstein-Barr virus associated lymphomahemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT06391814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391814.